--Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and...
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first...
- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 -...
MALVERN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic...
Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in...
- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of...
Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9...
Record Q2 Sales of $4.9 million, Q2 Net Earnings of $0.7 millionMISSISSAUGA, Ontario, May 12, 2022 (GLOBE NEWSWIRE) -- Microbix...
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative...
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19;...
- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to...
Transforms the company’s balance sheet with an equity financing to fund growth and a favourable resolution to amend the key...
Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to...
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)...
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No...
Jackson Center, Pennsylvania--(Newsfile Corp. - May 12, 2022) - Halberd Corporation (OTC Pink: HALB) submitted its fully audited financials through...
Recognition marks third consecutive year Hospital IQ has been named MedTech Breakthrough winner NEWTON, Mass.--(BUSINESS WIRE)--Hospital IQ, a leading intelligent...
GOLDEN, CO / ACCESSWIRE / May 12, 2022 / Panacea Life Sciences, Inc. (OTCQB:PLSH), ("Panacea" or the "Company"), a Colorado,...
SCHAFFHAUSEN, CH / ACCESSWIRE / May 12, 2022 / Occlutech Holding AGOcclutech Holding AG ("Occlutech"), one of the world's leading...